Abstract |
Exposure to moderate hyperoxia in prematurity contributes to subsequent airway dysfunction and increases the risk of developing recurrent wheeze and asthma. The nitric oxide (NO)- soluble guanylate cyclase (sGC)- cyclic GMP (cGMP) axis modulates airway tone by regulating airway smooth muscle (ASM) intracellular Ca(2+) ([Ca(2+)]i) and contractility. However, the effects of hyperoxia on this axis in the context of Ca(2+)/contractility are not known. In developing human ASM, we explored the effects of novel drugs that activate sGC independent of NO on alleviating hyperoxia (50% oxygen)-induced enhancement of Ca(2+) responses to bronchoconstrictor agonists. Treatment with BAY 41-2272 (sGC stimulator) and BAY 60-2770 (sGC activator) increased cGMP levels during exposure to 50% O2. Although 50% O2 did not alter sGCα1 or sGCβ1 expression, BAY 60-2770 did increase sGCβ1 expression. BAY 41-2272 and BAY 60-2770 blunted Ca(2+) responses to histamine in cells exposed to 50% O2. The effects of BAY 41-2272 and BAY 60-2770 were reversed by protein kinase G inhibition. These novel data demonstrate that BAY 41-2272 and BAY 60-2770 stimulate production of cGMP and blunt hyperoxia-induced increases in Ca(2+) responses in developing ASM. Accordingly, sGC stimulators/activators may be a useful therapeutic strategy in improving bronchodilation in preterm infants.
|
Authors | Rodney D Britt Jr, Michael A Thompson, Ine Kuipers, Alecia Stewart, Elizabeth R Vogel, James Thu, Richard J Martin, Christina M Pabelick, Y S Prakash |
Journal | American journal of physiology. Lung cellular and molecular physiology
(Am J Physiol Lung Cell Mol Physiol)
Vol. 309
Issue 6
Pg. L537-42
(Sep 15 2015)
ISSN: 1522-1504 [Electronic] United States |
PMID | 26254425
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Copyright | Copyright © 2015 the American Physiological Society. |
Chemical References |
- 3-(4-Amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridine
- 4-(((4-carboxybutyl) (2- (5-fluoro-2-((4'-(trifluoromethyl) biphenyl-4-yl)methoxy)phenyl)ethyl) amino)methyl)benzoic acid
- Benzoates
- Biphenyl Compounds
- Hydrocarbons, Fluorinated
- Pyrazoles
- Pyridines
- Receptors, Cytoplasmic and Nuclear
- Guanylate Cyclase
- Soluble Guanylyl Cyclase
- Cyclic GMP
- Oxygen
|
Topics |
- Benzoates
(pharmacology)
- Biphenyl Compounds
(pharmacology)
- Bronchi
(pathology)
- Calcium Signaling
- Cells, Cultured
- Cyclic GMP
(metabolism)
- Drug Evaluation, Preclinical
- Guanylate Cyclase
(antagonists & inhibitors, metabolism)
- Humans
- Hydrocarbons, Fluorinated
(pharmacology)
- Hyperoxia
(drug therapy, enzymology)
- Muscle, Smooth
(drug effects, embryology, pathology)
- Myocytes, Smooth Muscle
(drug effects, metabolism)
- Oxygen
(physiology)
- Pyrazoles
(pharmacology)
- Pyridines
(pharmacology)
- Receptors, Cytoplasmic and Nuclear
(antagonists & inhibitors, metabolism)
- Soluble Guanylyl Cyclase
- Trachea
(pathology)
|